A safety and feasibility study of cell therapy in dilated cardiomyopathy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Medical and Biological Research |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001000011 |
Resumo: | The aim of this study was to determine if bone marrow mononuclear cell (BMMC) transplantation is safe for moderate to severe idiopathic dilated cardiomyopathy (IDC). Clinical trials have shown that this procedure is safe and effective for ischemic patients, but little information is available regarding non-ischemic patients. Twenty-four patients with IDC, optimized therapy, age 46 ± 11.6 years, 17 males, NYHA classes II-IV, and left ventricular ejection fraction <35% were enrolled in the study. Clinical evaluation at baseline and 6 months after stem cell therapy to assess heart function included echocardiogram, magnetic resonance imaging, cardiopulmonary test, Minnesota Quality of Life Questionnaire, and NYHA classification. After cell transplantation 1 patient showed a transient increase in enzyme levels and 2 patients presented arrhythmias that were reversed within 72 h. Four patients died during follow-up, between 6 and 12 weeks after therapy. Clinical evaluation showed improvement in most patients as reflected by statistically significant decreases in Minnesota Quality of Life Questionnaire (63 ± 17.9 baseline vs 28.8 ± 16.75 at 6 months) and in class III-IV NYHA patients (18/24 baseline vs 2/20 at 6 months). Cardiopulmonary exercise tests demonstrated increased peak oxygen consumption (12.2 ± 2.4 at baseline vs 15.8 ± 7.1 mL·kg-1·min-1 at 6 months) and walked distance (377.2 ± 85.4 vs 444.1 ± 77.9 m at 6 months) in the 6-min walk test, which was not accompanied by increased left ventricular ejection fraction. Our findings indicate that BMMC therapy in IDC patients with severe ventricular dysfunction is feasible and that larger, randomized and placebo-controlled trials are warranted. |
id |
ABDC-1_737329c4b57bb33a80b236746c93853c |
---|---|
oai_identifier_str |
oai:scielo:S0100-879X2010001000011 |
network_acronym_str |
ABDC-1 |
network_name_str |
Brazilian Journal of Medical and Biological Research |
repository_id_str |
|
spelling |
A safety and feasibility study of cell therapy in dilated cardiomyopathyBone marrow cellsMononuclear fractionAutologous transplantationEjection fractionTreadmill testDilated cardiomyopathyThe aim of this study was to determine if bone marrow mononuclear cell (BMMC) transplantation is safe for moderate to severe idiopathic dilated cardiomyopathy (IDC). Clinical trials have shown that this procedure is safe and effective for ischemic patients, but little information is available regarding non-ischemic patients. Twenty-four patients with IDC, optimized therapy, age 46 ± 11.6 years, 17 males, NYHA classes II-IV, and left ventricular ejection fraction <35% were enrolled in the study. Clinical evaluation at baseline and 6 months after stem cell therapy to assess heart function included echocardiogram, magnetic resonance imaging, cardiopulmonary test, Minnesota Quality of Life Questionnaire, and NYHA classification. After cell transplantation 1 patient showed a transient increase in enzyme levels and 2 patients presented arrhythmias that were reversed within 72 h. Four patients died during follow-up, between 6 and 12 weeks after therapy. Clinical evaluation showed improvement in most patients as reflected by statistically significant decreases in Minnesota Quality of Life Questionnaire (63 ± 17.9 baseline vs 28.8 ± 16.75 at 6 months) and in class III-IV NYHA patients (18/24 baseline vs 2/20 at 6 months). Cardiopulmonary exercise tests demonstrated increased peak oxygen consumption (12.2 ± 2.4 at baseline vs 15.8 ± 7.1 mL·kg-1·min-1 at 6 months) and walked distance (377.2 ± 85.4 vs 444.1 ± 77.9 m at 6 months) in the 6-min walk test, which was not accompanied by increased left ventricular ejection fraction. Our findings indicate that BMMC therapy in IDC patients with severe ventricular dysfunction is feasible and that larger, randomized and placebo-controlled trials are warranted.Associação Brasileira de Divulgação Científica2010-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001000011Brazilian Journal of Medical and Biological Research v.43 n.10 2010reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2010007500093info:eu-repo/semantics/openAccessMartino,H.F.Oliveira,P.S.Souza,F.C.Costa,P.C.Assunção e Silva,E.Villela,R.Gaze,M.Weitzel,L.H.Oliveira Jr.,A.Muccillo,F.B.Arvelo,S.N.S.Sá,R.Guimarães,T.C.F.Tura,B.R.Campos de Carvalho,A.C.eng2010-10-22T00:00:00Zoai:scielo:S0100-879X2010001000011Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2010-10-22T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false |
dc.title.none.fl_str_mv |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
title |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
spellingShingle |
A safety and feasibility study of cell therapy in dilated cardiomyopathy Martino,H.F. Bone marrow cells Mononuclear fraction Autologous transplantation Ejection fraction Treadmill test Dilated cardiomyopathy |
title_short |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
title_full |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
title_fullStr |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
title_full_unstemmed |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
title_sort |
A safety and feasibility study of cell therapy in dilated cardiomyopathy |
author |
Martino,H.F. |
author_facet |
Martino,H.F. Oliveira,P.S. Souza,F.C. Costa,P.C. Assunção e Silva,E. Villela,R. Gaze,M. Weitzel,L.H. Oliveira Jr.,A. Muccillo,F.B. Arvelo,S.N.S. Sá,R. Guimarães,T.C.F. Tura,B.R. Campos de Carvalho,A.C. |
author_role |
author |
author2 |
Oliveira,P.S. Souza,F.C. Costa,P.C. Assunção e Silva,E. Villela,R. Gaze,M. Weitzel,L.H. Oliveira Jr.,A. Muccillo,F.B. Arvelo,S.N.S. Sá,R. Guimarães,T.C.F. Tura,B.R. Campos de Carvalho,A.C. |
author2_role |
author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Martino,H.F. Oliveira,P.S. Souza,F.C. Costa,P.C. Assunção e Silva,E. Villela,R. Gaze,M. Weitzel,L.H. Oliveira Jr.,A. Muccillo,F.B. Arvelo,S.N.S. Sá,R. Guimarães,T.C.F. Tura,B.R. Campos de Carvalho,A.C. |
dc.subject.por.fl_str_mv |
Bone marrow cells Mononuclear fraction Autologous transplantation Ejection fraction Treadmill test Dilated cardiomyopathy |
topic |
Bone marrow cells Mononuclear fraction Autologous transplantation Ejection fraction Treadmill test Dilated cardiomyopathy |
description |
The aim of this study was to determine if bone marrow mononuclear cell (BMMC) transplantation is safe for moderate to severe idiopathic dilated cardiomyopathy (IDC). Clinical trials have shown that this procedure is safe and effective for ischemic patients, but little information is available regarding non-ischemic patients. Twenty-four patients with IDC, optimized therapy, age 46 ± 11.6 years, 17 males, NYHA classes II-IV, and left ventricular ejection fraction <35% were enrolled in the study. Clinical evaluation at baseline and 6 months after stem cell therapy to assess heart function included echocardiogram, magnetic resonance imaging, cardiopulmonary test, Minnesota Quality of Life Questionnaire, and NYHA classification. After cell transplantation 1 patient showed a transient increase in enzyme levels and 2 patients presented arrhythmias that were reversed within 72 h. Four patients died during follow-up, between 6 and 12 weeks after therapy. Clinical evaluation showed improvement in most patients as reflected by statistically significant decreases in Minnesota Quality of Life Questionnaire (63 ± 17.9 baseline vs 28.8 ± 16.75 at 6 months) and in class III-IV NYHA patients (18/24 baseline vs 2/20 at 6 months). Cardiopulmonary exercise tests demonstrated increased peak oxygen consumption (12.2 ± 2.4 at baseline vs 15.8 ± 7.1 mL·kg-1·min-1 at 6 months) and walked distance (377.2 ± 85.4 vs 444.1 ± 77.9 m at 6 months) in the 6-min walk test, which was not accompanied by increased left ventricular ejection fraction. Our findings indicate that BMMC therapy in IDC patients with severe ventricular dysfunction is feasible and that larger, randomized and placebo-controlled trials are warranted. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001000011 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001000011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0100-879X2010007500093 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research v.43 n.10 2010 reponame:Brazilian Journal of Medical and Biological Research instname:Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
instname_str |
Associação Brasileira de Divulgação Científica (ABDC) |
instacron_str |
ABDC |
institution |
ABDC |
reponame_str |
Brazilian Journal of Medical and Biological Research |
collection |
Brazilian Journal of Medical and Biological Research |
repository.name.fl_str_mv |
Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC) |
repository.mail.fl_str_mv |
bjournal@terra.com.br||bjournal@terra.com.br |
_version_ |
1754302938989199360 |